World Health Organization Sounds Alert Over Severe Lack of Weight-Loss Jabs
Fewer than 10% of patients eligible to benefit from obesity jabs like Wegovy have access to them, states the global health agency as it issues its first recommendations on the therapies.
Considering more than one billion individuals worldwide currently living with obesity, it is calling for increased and just availability to this class of drugs.
Per forecasts, over two billion will be obese by 2030 if no action is taken.
"The latest guidance acknowledges that obesity is a chronic disease that can be treated with comprehensive and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are key obstacles to universal access to the treatments that can assist patients in reducing significant weight, explains the organization.
Weight-Loss Drug Scarcity
Despite the present most optimistic case, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of eligible patients, according to the WHO.
The guideline urges nations and manufacturers to expand availability, via approaches such as patent sharing.
A patent on the active ingredient – the core component of a leading brand – is due to expire in several nations in 2026.
How Obesity Drugs Function
These medications mimick a natural hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so individuals eat less.
Individuals typically start to lose weight after several weeks of commencing the once-weekly jabs.
Research suggests users may put most of the weight back on a year later of stopping the medication, because their typical appetite return.
To be overweight or obese elevates your chance for contracting health problems, like type 2 diabetes, heart disease, stroke, and specific cancers.
Obesity impacts people in all nations and was associated with millions of fatalities worldwide in 2024, according to the WHO.
